HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE)

Satellos Bioscience (NASDAQ:MSLE)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 87.30% from the company’s current price.

Several other brokerages also recently weighed in on MSLE. Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Guggenheim assumed coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price objective on the stock. Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Finally, Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a report on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Satellos Bioscience currently has an average rating of “Moderate Buy” and an average price target of $19.75.

Satellos Bioscience Price Performance

Shares of NASDAQ:MSLE opened at $9.61 on Monday. Satellos Bioscience has a 1-year low of $4.84 and a 1-year high of $13.39. The stock has a market capitalization of $200.27 million, a P/E ratio of -5.00 and a beta of 1.51. The firm’s 50 day moving average price is $8.21.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). As a group, research analysts expect that Satellos Bioscience will post -1.69 EPS for the current year.

Institutional Trading of Satellos Bioscience

An institutional investor recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. grew its position in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company’s stock after purchasing an additional 90,000 shares during the period. AWM Investment Company Inc. owned approximately 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent reporting period.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.